Overactive bladder – 18 years – Part II
Open Access
- 1 April 2016
- journal article
- review article
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 42 (2) , 199-214
Abstract
Traditionally, the treatment of overactive bladder syndrome has been based on the use of oral medications with the purpose of reestablishing the detrusor stability. The recent better understanding of the urothelial physiology fostered conceptual changes, and the oral anticholinergics – pillars of the overactive bladder pharmacotherapy – started to be not only recognized for their properties of inhibiting the detrusor contractile activity, but also their action on the bladder afference, and therefore, on the reduction of the symptoms that constitute the syndrome. Beta-adrenergic agonists, which were recently added to the list of drugs for the treatment of overactive bladder, still wait for a definitive positioning – as either a second-line therapy or an adjuvant to oral anticholinergics. Conservative treatment failure, whether due to unsatisfactory results or the presence of adverse side effects, define it as refractory overactive bladder. In this context, the intravesical injection of botulinum toxin type A emerged as an effective option for the existing gap between the primary measures and more complex procedures such as bladder augmentation. Sacral neuromodulation, described three decades ago, had its indication reinforced in this overactive bladder era. Likewise, the electric stimulation of the tibial nerve is now a minimally invasive alternative to treat those with refractory overactive bladder. The results of the systematic literature review on the oral pharmacological treatment and the treatment of refractory overactive bladder gave rise to this second part of the review article Overactive Bladder – 18 years, prepared during the 1st Latin-American Consultation on Overactive Bladder.Keywords
This publication has 161 references indexed in Scilit:
- A phase II dose-ranging study of mirabegron in patients with overactive bladderInternational Urogynecology Journal, 2013
- Percutaneous Tibial Nerve Stimulation in Treatment of Overactive Bladder: When Should Retreatment Be Started?Urology, 2011
- Is the Screening Method of Sacral Neuromodulation a Prognostic Factor for Long-Term Success?Journal of Urology, 2011
- Patient‐reported reasons for discontinuing overactive bladder medicationBJU International, 2010
- Comparison of intravaginal electrical stimulation and trospium hydrochloride in women with overactive bladder syndrome: a randomized controlled studyClinical Rehabilitation, 2010
- Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head‐to‐head placebo‐controlled trialBJU International, 2009
- Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive BladderJournal of Urology, 2009
- A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Antimuscarinic Drugs for Overactive BladderEuropean Urology, 2008
- The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-AnalysisEuropean Urology, 2008
- Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderBritish Journal of Pharmacology, 2006